-
-
-
-
-
-
-
Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: ARK Investment Management LLC
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) PT Lowered to $17 at Leerink Partners
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase Deficiency Program
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Receives U.S. FDA Fast Track Designation for the STARRĀ® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Misses Q4 EPS by 92c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Arcturus Therapeutics (ARCT)
-
443,913 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

